Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.50 |
| ▸ | TACR2 | P21452 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442135 | 0.95 | FPR2 (0.58) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6020387 | 0.91 | CHRM3 (0.46) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6020929 | 0.91 | CTSS (0.57) | FPR2CTSSCTSKCTSLCTSB | |
| SCHEMBL6019710 | 0.90 | CTSS (0.49) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6020102 | 0.87 | FPR2 (0.67) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6021080 | 0.86 | TRPV1 (0.41) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6020189 | 0.86 | CTSS (0.57) | FPR2TACR2CTSSCTSKCTSL | |
| SCHEMBL6020705 | 0.85 | FPR2 (0.69) | FPR2TACR2CTSSCTSLCTSB | |
| SCHEMBL6020288 | 0.84 | FPR2 (0.56) | FPR2CTSSCTSKCTSLCTSB | |
| SCHEMBL6020298 | 0.83 | CTSS (0.55) | FPR2CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | FPR2 3247/4885TACR2 2567/4885CTSS 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.